TNF and synovitis: The rationale for using anakinra was to address the uncertainty between infectious and post-infectious synovitis, opting for a short-acting targeted treatment before committing to long-term therapy with conventional DMARDs, such as methotrexate or anti-TNF biological response modifiers.